<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00440557</url>
  </required_header>
  <id_info>
    <org_study_id>CR010411</org_study_id>
    <secondary_id>EPOAKD3001</secondary_id>
    <nct_id>NCT00440557</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease</brief_title>
  <official_title>A Randomized, Open Label, Multicenter Study of Epoetin Alfa Comparing Two Extended-Dosing Regimens, Once-Weekly and Every-Two-Weeks, With the Three-Times-Weekly Dosing Regimen for Initiation and Maintenance Treatment in Anemic Subjects With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that once weekly and once every-2-weeks treatment
      with epoetin alfa, in patients with anemia associated with chronic kidney disease, is not
      less effective than the approved treatment with epoetin alfa that is given 3 times weekly
      with respect to changes in hemoglobin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a open-label (all people know the identity of the intervention), randomized (the
      study medication is assigned by chance), multicenter study designed to show that 2
      alternative dosing regimens, once weekly and once every-2-weeks (given at doses equivalent to
      50 IU/kg 3 times a week) are not inferior to the 3-times-weekly dosing regimen. Approximately
      375 patients with anemia will be enrolled in this study. Patients will be randomly assigned
      to receive epoetin alfa by subcutaneous (SC) injection according to one of the following 3
      regimens: 3 times weekly (Group 1), once weekly (Group 2), or once every 2 weeks (Group 3)
      for 22 weeks. Thereafter, patients in Group 1 will be switched to the once-weekly dosing
      regimen for an additional 22 weeks, and patients in Groups 2 and 3 will continue their
      current treatment for an additional 22 weeks. The total duration of the open-label treatment
      phase is 44 weeks which will include initiation and maintenance treatment periods (with the
      goal of increasing, then maintaining, the hemoglobin level between 11.0 and 11.9 g/dL
      inclusive) and a safety period (to assess longer exposure to epoetin alfa treatment and any
      period of hemoglobin instability during the transition from 3-times-weekly to once-weekly
      dosing). Starting doses of epoetin alfa in the 3-times-weekly, once-weekly, and every-2-weeks
      groups will be 50 IU/kg, 10,000 IU, and 20,000 IU, respectively; thereafter adjusted
      according to weekly hemoglobin concentrations. Safety evaluations will include assessment of
      adverse events, laboratory tests, physical examinations, and vital signs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22</measure>
    <time_frame>From baseline through Week 22</time_frame>
    <description>The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included in calculating the average Hb during the last 8 weeks of treatment through Week 22.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With an Increase of â‰¥1 g/dL in Hb Concentration From Baseline by Week 9</measure>
    <time_frame>From baseline to Week 9</time_frame>
    <description>The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Hb increase is defined as the post-baseline Hb level minus the baseline Hb level.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Participants Who Exceeded a Hb Concentration of 11.9 g/dL During First 22 Weeks of Treatment</measure>
    <time_frame>From baseline to Week 22</time_frame>
    <description>The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. participants who exceed a Hb value of 11.9 g/dL at least once were included in the numerator of the percentage calculation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Maximum Hb Concentration (g/dL) During First 22 Weeks of Treatment</measure>
    <time_frame>From baseline to Week 22</time_frame>
    <description>The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. A maximum Hb observation was identified for each participant during the first 22 weeks of treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Participants Who Met or Exceeded Hb Rate of Rise &gt;=1.0 g/dL/2 Weeks During First 22 Weeks of Treatment</measure>
    <time_frame>From baseline to Week 22</time_frame>
    <description>Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Participants Who Met or Exceeded Hb Rate of Rise &gt;=1.5 g/dL/2 Weeks During First 22 Weeks of Treatment</measure>
    <time_frame>From baseline to Week 22</time_frame>
    <description>Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.5 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Particpants Who Met or Exceeded Hb Rate of Rise &gt;=2.0 g/dL/2 Weeks During First 22 Weeks of Treatment</measure>
    <time_frame>From baseline to Week 22</time_frame>
    <description>Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 2.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">375</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>TIW: Epoetin alfa 3 injections Weekly/Once Weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QW: Epoetin alfa once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Q2W: Epoetin alfa once every two weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa 3 times weekly /once weekly</intervention_name>
    <description>Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)</description>
    <arm_group_label>TIW: Epoetin alfa 3 injections Weekly/Once Weekly</arm_group_label>
    <other_name>PROCRIT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa once weekly</intervention_name>
    <description>Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).</description>
    <arm_group_label>QW: Epoetin alfa once weekly</arm_group_label>
    <other_name>PROCRIT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa once every two weeks</intervention_name>
    <description>Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).</description>
    <arm_group_label>Q2W: Epoetin alfa once every two weeks</arm_group_label>
    <other_name>PROCRIT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet the diagnostic criteria for chronic kidney disease, defined as a glomerular
             filtration rate (GFR) more than or equal to 15 mL/min per 1.73 m2 and less than 60
             mL/min per 1.73 m2 (Stages 3 and 4) as calculated by the central laboratory

          -  Require support of an erythropoietin receptor agonist

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Serum ferritin level less than 50 ng/mL

          -  Serum iron overload

          -  Severe congestive heart failure

          -  Active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research and Development, L.L C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lynwood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Visalia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yuba City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carrollton</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Statesboro</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Old Bridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hartford</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield Gardens</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bamberg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dyersburg</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caguas</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=32&amp;filename=CR010411_CSR.pdf</url>
    <description>A Randomized,Open-Label, Multicenter Study of Epoetin Alfa Comparing Two Extended-Dosing Regimens,OnceWeekly and EveryTwoWeeks,With the ThreeTimesWeekly Dosing Regimen for Initiation &amp; Maintenance Treatment in Anemic Subjects With Chronic Kidney Disease</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2007</study_first_submitted>
  <study_first_submitted_qc>February 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2007</study_first_posted>
  <results_first_submitted>February 23, 2009</results_first_submitted>
  <results_first_submitted_qc>February 2, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2010</results_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia</keyword>
  <keyword>Chronic Kidney disease</keyword>
  <keyword>Kidney disease</keyword>
  <keyword>Epoetin alfa</keyword>
  <keyword>Procrit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was initiated 29 August 2006 and completed on 21 February 2008. Subjects were screened for eligibility at 64 investigative sites within the U.S. Three hundred seventy-five subjects (intent to treat) were randomly assigned to a treatment group by 52 investigators from 56 sites. Safety population consisted of 373 subjects.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)</title>
          <description>Epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)</description>
        </group>
        <group group_id="P2">
          <title>Epoetin Alfa:Once Weekly (QW)</title>
          <description>Epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU)</description>
        </group>
        <group group_id="P3">
          <title>Epoetin Alfa:Once Every Two Weeks (Q2W)</title>
          <description>Epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="123">Safety population defined as all subjects who received at least 1 injection of study drug.</participants>
                <participants group_id="P2" count="125">Safety population defined as all subjects who received at least 1 injection of study drug.</participants>
                <participants group_id="P3" count="125">Safety population defined as all subjects who received at least 1 injection of study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Began Dialysis</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Principal Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Principal Investigator's office closed</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient transferred to nursing home</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient had surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)</title>
          <description>Epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)</description>
        </group>
        <group group_id="B2">
          <title>Epoetin Alfa:Once Weekly (QW)</title>
          <description>Epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU)</description>
        </group>
        <group group_id="B3">
          <title>Epoetin Alfa:Once Every Two Weeks (Q2W)</title>
          <description>Epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="123"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="125"/>
            <count group_id="B4" value="373"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.1" spread="13.02"/>
                    <measurement group_id="B2" value="68.9" spread="11.86"/>
                    <measurement group_id="B3" value="68.9" spread="13.02"/>
                    <measurement group_id="B4" value="69.6" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22</title>
        <description>The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included in calculating the average Hb during the last 8 weeks of treatment through Week 22.</description>
        <time_frame>From baseline through Week 22</time_frame>
        <population>Modified Intent-To-Treat (mITT) population. The mITT population was defined as all participants who were randomized and had at least 1 postrandomization hemoglobin concentration measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)</title>
            <description>Epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa:Once Weekly (QW)</title>
            <description>Epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa:Once Every Two Weeks (Q2W)</title>
            <description>Epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22</title>
          <description>The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included in calculating the average Hb during the last 8 weeks of treatment through Week 22.</description>
          <population>Modified Intent-To-Treat (mITT) population. The mITT population was defined as all participants who were randomized and had at least 1 postrandomization hemoglobin concentration measurement.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.910"/>
                    <measurement group_id="O2" value="1.59" spread="0.997"/>
                    <measurement group_id="O3" value="1.27" spread="0.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the mean change in Hb concentration from baseline to the average of the last 8 weeks of treatment (tX) through Week 22 in the QW group is not lower than that of the TIW group by more than 1 g/dL.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Assuming a difference in the mean change in Hb from baseline to the average of the last 8 weeks of treatment through Week 22 of -0.3 g/dL between standard-tx group (TIW) and test-tx group (QW), a pooled standard deviation of 1.7 g/dL, and a noninferiority margin of 1 g/dL, a sample size of approximately 250 participants (125 per group) will provide 90% power to demonstrate that the test treatment group is not inferior to the standard-treatment group for an overall 2-sided 0.05 significance level</non_inferiority_desc>
            <param_type>Difference of Least Squares Means</param_type>
            <param_value>-0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.106</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.380</ci_lower_limit>
            <ci_upper_limit>0.037</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is the mean change in Hb concentration from baseline to the average of the last 8 weeks of treatment through Week 22 in the Q2W group is not lower than that of the TIW group by more than 1 g/dL.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Assuming a difference in the mean change in Hb from baseline to the average of the last 8 weeks of treatment through Week 22 of -0.3 g/dL between standard-tx group (TIW) and test-tx group (QW), a pooled standard deviation of 1.7 g/dL, and a noninferiority margin of 1 g/dL, a sample size of approximately 250 participants (125 per group) will provide 90% power to demonstrate that the test treatment group is not inferior to the standard-treatment group for an overall 2-sided 0.05 significance level</non_inferiority_desc>
            <param_type>Difference of Least Squares Means</param_type>
            <param_value>-0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.107</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.641</ci_lower_limit>
            <ci_upper_limit>-0.221</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Participants Who Exceeded a Hb Concentration of 11.9 g/dL During First 22 Weeks of Treatment</title>
        <description>The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. participants who exceed a Hb value of 11.9 g/dL at least once were included in the numerator of the percentage calculation.</description>
        <time_frame>From baseline to Week 22</time_frame>
        <population>Safety population. The safety population was defined as all participants who received at least 1 injection of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)</title>
            <description>Epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa:Once Weekly (QW)</title>
            <description>Epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa:Once Every Two Weeks (Q2W)</title>
            <description>Epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU)</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Exceeded a Hb Concentration of 11.9 g/dL During First 22 Weeks of Treatment</title>
          <description>The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. participants who exceed a Hb value of 11.9 g/dL at least once were included in the numerator of the percentage calculation.</description>
          <population>Safety population. The safety population was defined as all participants who received at least 1 injection of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-7.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.2</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-15.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-25.0</ci_lower_limit>
            <ci_upper_limit>-5.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Maximum Hb Concentration (g/dL) During First 22 Weeks of Treatment</title>
        <description>The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. A maximum Hb observation was identified for each participant during the first 22 weeks of treatment.</description>
        <time_frame>From baseline to Week 22</time_frame>
        <population>Safety population. The safety population was defined as all participants who received at least 1 injection of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)</title>
            <description>Epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa:Once Weekly (QW)</title>
            <description>Epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa:Once Every Two Weeks (Q2W)</title>
            <description>Epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Hb Concentration (g/dL) During First 22 Weeks of Treatment</title>
          <description>The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. A maximum Hb observation was identified for each participant during the first 22 weeks of treatment.</description>
          <population>Safety population. The safety population was defined as all participants who received at least 1 injection of study drug.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.87" spread="1.176"/>
                    <measurement group_id="O2" value="12.61" spread="1.158" lower_limit="-0.564" upper_limit="0.043"/>
                    <measurement group_id="O3" value="12.42" spread="1.310" lower_limit="-0.755" upper_limit="-0.147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference of Least Squares Means</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.564</ci_lower_limit>
            <ci_upper_limit>0.043</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference of Least Squares Means</param_type>
            <param_value>-0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.755</ci_lower_limit>
            <ci_upper_limit>-0.147</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Participants Who Met or Exceeded Hb Rate of Rise &gt;=1.0 g/dL/2 Weeks During First 22 Weeks of Treatment</title>
        <description>Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.</description>
        <time_frame>From baseline to Week 22</time_frame>
        <population>Safety population. The safety population was defined as all subjects who received at least 1 injection of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)</title>
            <description>Epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa:Once Weekly (QW)</title>
            <description>Epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa:Once Every Two Weeks (Q2W)</title>
            <description>Epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU)</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Met or Exceeded Hb Rate of Rise &gt;=1.0 g/dL/2 Weeks During First 22 Weeks of Treatment</title>
          <description>Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.</description>
          <population>Safety population. The safety population was defined as all subjects who received at least 1 injection of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="116"/>
                    <measurement group_id="O3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-5.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-11.4</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Participants Who Met or Exceeded Hb Rate of Rise &gt;=1.5 g/dL/2 Weeks During First 22 Weeks of Treatment</title>
        <description>Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.5 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.</description>
        <time_frame>From baseline to Week 22</time_frame>
        <population>Safety population. The safety population was defined as all participants who received at least 1 injection of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)</title>
            <description>Epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa:Once Weekly (QW)</title>
            <description>Epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa:Once Every Two Weeks (Q2W)</title>
            <description>Epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU)</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Met or Exceeded Hb Rate of Rise &gt;=1.5 g/dL/2 Weeks During First 22 Weeks of Treatment</title>
          <description>Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 1.5 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.</description>
          <population>Safety population. The safety population was defined as all participants who received at least 1 injection of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.2</ci_lower_limit>
            <ci_upper_limit>8.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-9.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-21.7</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Particpants Who Met or Exceeded Hb Rate of Rise &gt;=2.0 g/dL/2 Weeks During First 22 Weeks of Treatment</title>
        <description>Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 2.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.</description>
        <time_frame>From baseline to Week 22</time_frame>
        <population>Safety population. The safety population was defined as all participants who received at least 1 injection of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)</title>
            <description>Epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa:Once Weekly (QW)</title>
            <description>Epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa:Once Every Two Weeks (Q2W)</title>
            <description>Epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU)</description>
          </group>
        </group_list>
        <measure>
          <title>Particpants Who Met or Exceeded Hb Rate of Rise &gt;=2.0 g/dL/2 Weeks During First 22 Weeks of Treatment</title>
          <description>Change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Participants who met or exceeded a Hb Rate of Rise (RR) of 2.0 g/dL/2 weeks at least once were included in the numerator of the percentage calculation.</description>
          <population>Safety population. The safety population was defined as all participants who received at least 1 injection of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.6</ci_lower_limit>
            <ci_upper_limit>14.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-3.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-15.0</ci_lower_limit>
            <ci_upper_limit>9.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Maximum (Max) Hb Rate (g/dL/2 Weeks) of Rise During First 22 Weeks of Treatment</title>
        <description>Change is calculated as mean hemoglobin (Hb) over last 8 wks subtracts baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Max Hb RR observation was identified for each participant during the 1st 22 wks of treatment. This was the max RR in hemoglobin over any 2-wk period per participant.</description>
        <time_frame>From baseline to Week 22</time_frame>
        <population>Safety population. The safety population was defined as all participants who received at least 1 injection of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)</title>
            <description>Epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa:Once Weekly (QW)</title>
            <description>Epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa:Once Every Two Weeks (Q2W)</title>
            <description>Epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum (Max) Hb Rate (g/dL/2 Weeks) of Rise During First 22 Weeks of Treatment</title>
          <description>Change is calculated as mean hemoglobin (Hb) over last 8 wks subtracts baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Max Hb RR observation was identified for each participant during the 1st 22 wks of treatment. This was the max RR in hemoglobin over any 2-wk period per participant.</description>
          <population>Safety population. The safety population was defined as all participants who received at least 1 injection of study drug.</population>
          <units>g/dL/2 weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.839"/>
                    <measurement group_id="O2" value="2.02" spread="1.008" lower_limit="-0.210" upper_limit="0.270"/>
                    <measurement group_id="O3" value="1.92" spread="1.027" lower_limit="-0.315" upper_limit="0.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference of Least Squares Means</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.210</ci_lower_limit>
            <ci_upper_limit>0.270</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference of Least Squares Means</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.315</ci_lower_limit>
            <ci_upper_limit>0.166</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With an Increase of â‰¥1 g/dL in Hb Concentration From Baseline by Week 9</title>
        <description>The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Hb increase is defined as the post-baseline Hb level minus the baseline Hb level.</description>
        <time_frame>From baseline to Week 9</time_frame>
        <population>Modified Intent-To-Treat (mITT) population. The mITT population was defined as all participants who were randomized and had at least 1 postrandomization Hb concentration measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)</title>
            <description>Epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)</description>
          </group>
          <group group_id="O2">
            <title>Epoetin Alfa:Once Weekly (QW)</title>
            <description>Epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU)</description>
          </group>
          <group group_id="O3">
            <title>Epoetin Alfa:Once Every Two Weeks (Q2W)</title>
            <description>Epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU)</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With an Increase of â‰¥1 g/dL in Hb Concentration From Baseline by Week 9</title>
          <description>The change is calculated as average hemoglobin (Hb) over the last 8 weeks subtracts the baseline Hb. Only Hb measurements up until a participant receives a transfusion or begins dialysis were included. Hb increase is defined as the post-baseline Hb level minus the baseline Hb level.</description>
          <population>Modified Intent-To-Treat (mITT) population. The mITT population was defined as all participants who were randomized and had at least 1 postrandomization Hb concentration measurement.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="124"/>
                <count group_id="O3" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-8.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-16</ci_lower_limit>
            <ci_upper_limit>-1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage of Participants</param_type>
            <param_value>-10.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-18.0</ci_lower_limit>
            <ci_upper_limit>-3.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>44 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Epoetin Alfa:Three Injections Weekly (TIW)/Once Weekly (QW)</title>
          <description>Epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)</description>
        </group>
        <group group_id="E2">
          <title>Epoetin Alfa:Once Weekly (QW)</title>
          <description>Epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU)</description>
        </group>
        <group group_id="E3">
          <title>Epoetin Alfa:Once Every Two Weeks (Q2W)</title>
          <description>Epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Subendocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Device electrical finding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Failure to capture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Hyperammonaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Oral intake reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastitic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Encephalomalacia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Walking disability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Arterial stenosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="125"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Disclosure restrictions on the PI are pre- review of publications prior to public release. Sponsor can embargo trial result publication for up to 120 days. The PI may not publish the sponsor's confidential information without consent. In multi-center trials, individual PI's may publish results only if the study group has not published results 12 months after study completion, abandonment, or termination. The sponsor cannot require changes to the scientific content and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr Director of Clinical Research</name_or_title>
      <organization>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</organization>
      <phone>908-927-2116</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

